{"id":"https://openalex.org/W1968797216","doi":"https://doi.org/10.1186/s12885-015-1029-z","title":"Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance","display_name":"Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance","publication_year":2015,"publication_date":"2015-02-17","ids":{"openalex":"https://openalex.org/W1968797216","doi":"https://doi.org/10.1186/s12885-015-1029-z","mag":"1968797216","pmid":"https://pubmed.ncbi.nlm.nih.gov/25886620","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4340232"},"language":"en","primary_location":{"id":"doi:10.1186/s12885-015-1029-z","doi":"https://doi.org/10.1186/s12885-015-1029-z","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12885-015-1029-z","pdf_url":"https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-015-1029-z","source":{"id":"https://openalex.org/S192926780","display_name":"BMC Cancer","issn_l":"1471-2407","issn":["1471-2407"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Cancer","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-015-1029-z","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036211173","display_name":"Jennifer J. Wheler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jennifer Wheler","raw_affiliation_strings":["Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. jjwheler@mdanderson.org","Department of Investigational Cancer Therapeutics \u2013 a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, Houston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. jjwheler@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics \u2013 a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, Houston, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079433880","display_name":"Roman Yelensky","orcid":"https://orcid.org/0000-0002-5356-0111","observed_orcids":["https://orcid.org/0000-0002-5356-0111"]},"institutions":[{"id":"https://openalex.org/I4392738181","display_name":"Foundation Medicine (United States)","ror":"https://ror.org/02ackr434","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4392738181"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roman Yelensky","raw_affiliation_strings":["Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. ryelensky@foundationmedicine.com","Foundation Medicine, Cambridge, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. ryelensky@foundationmedicine.com","institution_ids":["https://openalex.org/I4392738181"]},{"raw_affiliation_string":"Foundation Medicine, Cambridge, USA","institution_ids":["https://openalex.org/I4392738181"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069777765","display_name":"Gerald Steven Falchook","orcid":"https://orcid.org/0000-0001-9165-2191","observed_orcids":["https://orcid.org/0000-0001-9165-2191"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gerald Falchook","raw_affiliation_strings":["Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. gfalchoo@mdanderson.org","Department of Investigational Cancer Therapeutics \u2013 a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, Houston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. gfalchoo@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics \u2013 a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, Houston, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015498468","display_name":"Kevin B. Kim","orcid":"https://orcid.org/0000-0003-0694-0530","observed_orcids":["https://orcid.org/0000-0003-0694-0530"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin B Kim","raw_affiliation_strings":["Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. kkim@mdanderson.org","Department of Melanoma Medical Oncology, the University of Texas, MD Anderson Cancer Center, Houston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. kkim@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Melanoma Medical Oncology, the University of Texas, MD Anderson Cancer Center, Houston, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033798832","display_name":"Patrick Hwu","orcid":"https://orcid.org/0000-0002-8293-1313","observed_orcids":["https://orcid.org/0000-0002-8293-1313","https://orcid.org/0000-0003-0554-2856"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Hwu","raw_affiliation_strings":["Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. phwu@mdanderson.org","Department of Melanoma Medical Oncology, the University of Texas, MD Anderson Cancer Center, Houston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. phwu@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Melanoma Medical Oncology, the University of Texas, MD Anderson Cancer Center, Houston, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044840107","display_name":"Apostolia Maria Tsimberidou","orcid":"https://orcid.org/0000-0003-2713-233X","observed_orcids":["https://orcid.org/0000-0003-2713-233X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Apostolia M Tsimberidou","raw_affiliation_strings":["Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. atsimber@mdanderson.org","Department of Investigational Cancer Therapeutics \u2013 a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, Houston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. atsimber@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics \u2013 a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, Houston, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113642947","display_name":"Philip J. Stephens","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4392738181","display_name":"Foundation Medicine (United States)","ror":"https://ror.org/02ackr434","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4392738181"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip J Stephens","raw_affiliation_strings":["Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. pstephens@foundationmedicine.com","Foundation Medicine, Cambridge, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. pstephens@foundationmedicine.com","institution_ids":["https://openalex.org/I4392738181"]},{"raw_affiliation_string":"Foundation Medicine, Cambridge, USA","institution_ids":["https://openalex.org/I4392738181"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Hong","raw_affiliation_strings":["Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. dshong@mdanderson.org","Department of Investigational Cancer Therapeutics \u2013 a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, Houston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. dshong@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics \u2013 a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, Houston, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104111148","display_name":"Maureen T. Cronin","orcid":"https://orcid.org/0000-0003-3208-829X","observed_orcids":["https://orcid.org/0000-0003-3208-829X"]},"institutions":[{"id":"https://openalex.org/I4392738181","display_name":"Foundation Medicine (United States)","ror":"https://ror.org/02ackr434","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4392738181"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maureen T Cronin","raw_affiliation_strings":["Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. mcronin@foundationmedicine.com","Foundation Medicine, Cambridge, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. mcronin@foundationmedicine.com","institution_ids":["https://openalex.org/I4392738181"]},{"raw_affiliation_string":"Foundation Medicine, Cambridge, USA","institution_ids":["https://openalex.org/I4392738181"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA. rkurzrock@mail.ucsd.edu","Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, La Jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA. rkurzrock@mail.ucsd.edu","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]},{"raw_affiliation_string":"Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, La Jolla, USA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5036211173"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":3390,"currency":"USD","value_usd":3390},"apc_paid":{"value":3390,"currency":"USD","value_usd":3390},"fwci":2.6033,"has_fulltext":true,"cited_by_count":28,"citation_normalized_percentile":{"value":0.90265958,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"15","issue":"1","first_page":"61","last_page":"61"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/braf-mutant-melanoma","display_name":"BRAF-mutant melanoma","score":0.9700000286102295},{"id":"https://openalex.org/keywords/braf-inhibitors","display_name":"BRAF inhibitors","score":0.9139999747276306},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":1.0},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.7139999866485596},{"id":"https://openalex.org/keywords/exceptional-responders","display_name":"exceptional responders","score":0.8309999704360962},{"id":"https://openalex.org/keywords/durable-complete-response","display_name":"durable complete response","score":0.7509999871253967},{"id":"https://openalex.org/keywords/tumor-genomic-alterations","display_name":"tumor genomic alterations","score":0.7179999947547913},{"id":"https://openalex.org/keywords/nras-mutation","display_name":"NRAS mutation","score":0.7730000019073486},{"id":"https://openalex.org/keywords/apc-mutation","display_name":"APC mutation","score":0.7149999737739563},{"id":"https://openalex.org/keywords/nf1-mutation","display_name":"NF1 mutation","score":0.875},{"id":"https://openalex.org/keywords/gene-amplification","display_name":"gene amplification","score":0.6990000009536743},{"id":"https://openalex.org/keywords/cdkn2a-b-deletion","display_name":"CDKN2A/B deletion","score":0.8429999947547913},{"id":"https://openalex.org/keywords/rb1","display_name":"RB1","score":0.7400000095367432},{"id":"https://openalex.org/keywords/atm","display_name":"ATM","score":0.9890000224113464},{"id":"https://openalex.org/keywords/tumor-heterogeneity","display_name":"tumor heterogeneity","score":0.7940000295639038},{"id":"https://openalex.org/keywords/molecular-evolution","display_name":"molecular evolution","score":0.7609999775886536},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.5519999861717224}],"concepts":[{"id":"https://openalex.org/C21790070","wikidata":"https://www.wikidata.org/wiki/Q18030215","display_name":"Neuroblastoma RAS viral oncogene homolog","level":5,"score":0.863572359085083},{"id":"https://openalex.org/C2780265364","wikidata":"https://www.wikidata.org/wiki/Q5009957","display_name":"CDKN2A","level":3,"score":0.7906140089035034},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.7191442251205444},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6714972853660583},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.6224324107170105},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.6045571565628052},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.6021733283996582},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.5906819105148315},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5700894594192505},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4840356707572937},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.44926097989082336},{"id":"https://openalex.org/C36823959","wikidata":"https://www.wikidata.org/wiki/Q373027","display_name":"Exon","level":3,"score":0.4438122808933258},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4303264319896698},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.4171207547187805},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3796723783016205},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.3232951760292053},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.2505236566066742},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.23236066102981567},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.22176498174667358},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.1759483814239502},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.12848645448684692},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.1119774580001831}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059014","descriptor_name":"High-Throughput Nucleotide Sequencing","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true}],"locations_count":6,"locations":[{"id":"doi:10.1186/s12885-015-1029-z","doi":"https://doi.org/10.1186/s12885-015-1029-z","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12885-015-1029-z","pdf_url":"https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-015-1029-z","source":{"id":"https://openalex.org/S192926780","display_name":"BMC Cancer","issn_l":"1471-2407","issn":["1471-2407"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Cancer","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:3304212","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4340232","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4340232","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4340232","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Cancer","raw_type":"Text"},{"id":"pmid:25886620","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25886620","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC cancer","raw_type":"Journal Article"},{"id":"pmh:oai:escholarship.org/ark:/13030/qt82j5c18p","doi":null,"is_oa":false,"landing_page_url":"https://escholarship.org/uc/item/82j5c18p","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"BMC cancer, vol 15, iss 1","raw_type":"article"},{"id":"pmh:oai:escholarship.org:ark:/13030/qt82j5c18p","doi":null,"is_oa":true,"landing_page_url":"https://escholarship.org/uc/item/82j5c18p","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"BMC Cancer, vol 15, iss 1","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1186/s12885-015-1029-z","doi":"https://doi.org/10.1186/s12885-015-1029-z","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12885-015-1029-z","pdf_url":"https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-015-1029-z","source":{"id":"https://openalex.org/S192926780","display_name":"BMC Cancer","issn_l":"1471-2407","issn":["1471-2407"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332521","display_name":"University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07"},{"id":"https://openalex.org/F4320334461","display_name":"Foundation Medicine","ror":"https://ror.org/02ackr434"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1968797216.pdf","grobid_xml":"https://content.openalex.org/works/W1968797216.grobid-xml"},"referenced_works_count":34,"referenced_works":["https://openalex.org/W1498471683","https://openalex.org/W1925900276","https://openalex.org/W1968804551","https://openalex.org/W1976107191","https://openalex.org/W1979618971","https://openalex.org/W1988379285","https://openalex.org/W1990376228","https://openalex.org/W1993739082","https://openalex.org/W2006985176","https://openalex.org/W2018336040","https://openalex.org/W2019607817","https://openalex.org/W2020543365","https://openalex.org/W2027517328","https://openalex.org/W2029147710","https://openalex.org/W2032211985","https://openalex.org/W2040474892","https://openalex.org/W2040524221","https://openalex.org/W2053473615","https://openalex.org/W2073104618","https://openalex.org/W2076668534","https://openalex.org/W2079576402","https://openalex.org/W2100614336","https://openalex.org/W2103894337","https://openalex.org/W2106494998","https://openalex.org/W2128542677","https://openalex.org/W2130875528","https://openalex.org/W2139248078","https://openalex.org/W2141300809","https://openalex.org/W2150575159","https://openalex.org/W2161724145","https://openalex.org/W2163188200","https://openalex.org/W2168143310","https://openalex.org/W2169614956","https://openalex.org/W2602152747"],"related_works":["https://openalex.org/W2746208952","https://openalex.org/W2995176265","https://openalex.org/W7170164149","https://openalex.org/W3000984240","https://openalex.org/W2336228219","https://openalex.org/W2891828091","https://openalex.org/W2008976980","https://openalex.org/W4384701376","https://openalex.org/W2551970119","https://openalex.org/W3045916235"],"abstract_inverted_index":{"BACKGROUND:":[0],"Patients":[1],"with":[2,12,28,84,211,231],"BRAF":[3,13,30,43,141,147,153,212,238,246],"mutation-positive":[4,31,213],"advanced":[5,29,214,232],"melanoma":[6,32,215,233],"respond":[7],"well":[8],"to":[9,78,109,136,152],"matched":[10],"therapy":[11,143],"or":[14,38,118,220],"MEK":[15,45],"inhibitors,":[16],"but":[17,222],"often":[18,72],"quickly":[19],"develop":[20],"resistance.":[21],"METHODS:":[22],"Tumor":[23],"tissue":[24,133],"from":[25,69],"ten":[26,94],"patients":[27,95,113,158,189,194,210,230],"who":[33,124,216],"achieved":[34,114,125,217],"partial":[35],"response":[36,40],"(PR)":[37],"complete":[39],"(CR)":[41],"on":[42,245],"and/or":[44],"inhibitors":[46],"was":[47,195],"analyzed":[48],"using":[49],"next":[50],"generation":[51],"sequencing":[52],"(NGS)":[53],"assay.":[54],"Genomic":[55],"libraries":[56],"were":[57],"captured":[58],"for":[59,207],"3230":[60],"exons":[61],"in":[62,74,150,156,161,167,177,183,209],"182":[63],"cancer-related":[64],"genes":[65,71],"plus":[66],"37":[67],"introns":[68],"14":[70],"rearranged":[73],"cancer":[75],"and":[76,131,164,174,179,185,190,240],"sequenced":[77],"average":[79],"median":[80],"depth":[81],"of":[82,86,92,98,139,229],"734X":[83],"99%":[85],"bases":[87],"covered":[88],">100X.":[89],"RESULTS:":[90],"Three":[91],"the":[93,137],"(median":[96],"number":[97],"prior":[99],"therapies":[100],"=":[101,107],"2)":[102],"attained":[103],"prolonged":[104],"CR":[105,126,221,244],"(duration":[106],"23.6+":[108],"28.7+":[110,129],"months);":[111],"seven":[112],"either":[115],"a":[116,119,146,218,237,242],"PR":[117,219],"short-lived":[120],"CR.":[121],"One":[122],"patient":[123],"ongoing":[127],"at":[128],"months":[130],"had":[132,144],"available":[134],"close":[135],"time":[138],"initiating":[140],"inhibitor":[142],"only":[145,236],"mutation.":[148],"Abnormalities":[149],"addition":[151],"mutation":[154,239],"found":[155],"other":[157],"included:":[159],"mutations":[160],"NRAS,":[162],"APC":[163],"NF1;":[165],"amplifications":[166],"BRAF,":[168],"aurora":[169],"kinase":[170],"A,":[171],"MYC,":[172],"MITF":[173],"MET;":[175],"deletions":[176],"CDKN2A/B":[178],"PAX5;":[180],"and,":[181],"alterations":[182,203],"RB1":[184],"ATM.":[186],"Heterogeneity":[187],"between":[188],"molecular":[191],"evolution":[192],"within":[193],"noted.":[196],"CONCLUSION:":[197],"NGS":[198],"identified":[199],"potentially":[200],"actionable":[201],"DNA":[202],"that":[204],"could":[205],"account":[206],"resistance":[208],"whose":[223],"tumors":[224],"later":[225],"progressed.":[226],"A":[227],"subset":[228],"may":[234],"harbor":[235],"achieve":[241],"durable":[243],"pathway":[247],"inhibitors.":[248]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":5}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}